Martin Graham, PhD
Retired CEO, Empire Discovery Institute
Dr. Martin Graham was the CEO of EDI between 2019 and 2022. He is a successful drug developer and serial entrepreneur with over 30 years of experience in the development of small molecule drugs and biologics including Oxaliplatin (colorectal cancer), Stelara (psoriasis), Remicade (rheumatoid arthritis & Crohn’s disease and Elitek (rasburicase) for tumor lysis syndrome. He brings a wealth of pharmaceutical industry experience with Sterling-Winthrop, Sanofi, Centocor, Johnson & Johnson, and venture-backed biotechnology companies including TetraLogic Pharmaceuticals.
Prior to joining EDI, Martin was the CEO, President, and Founder of PKPD Biosciences (a pharmacokinetic modeling & simulation company) which he merged with his second company KinderPharm, a pediatric drug
development company before being acquired by Synteract. Martin earned his PhD. from the University of London Drug Development Section, Institute of Cancer Research, Royal Marsden Hospital, London; his B.Sc. from the University of Leeds in Pharmacology and Microbiology; and is an Honorary Professor of Pharmacokinetic Modeling & Simulation at the School of Life Sciences, Institute of Pharmaceutical Innovation University of Bradford, England. Martin served as a Scientific Advisor to the Harrington Discovery Institute until joining EDI in 2019 and is currently a pharmacology consultant to BioMotiv, the early stage drug discovery accelerator that is part of the Harrington Project.
